UBE2N and Hypoglycemia: At 24-h, UBE2N (2927.0 ± 206.3 vs 3912.5 ± 267.2 RFU of UBE2N, 24-h post-hypoglycemia vs baseline, p < 0.01, Fig. 4A); STIP1 (3645.2 ± 211.9 vs 4656.4 ± 265.04, 24-h post-hypoglycemia vs baseline, p < 0.01, Fig. 4B) and UBE2L3 (788.3 ± 47.8 vs 945.6 ± 49.3 RFU of UBE2L3, 24-h post-hypoglycemia vs baseline, p < 0.04) (Fig. 4D) were decreased in controls, a change that was not seen for those with T2D.